37,000 AI agents flagged CD276 as a lung-cancer drug target

A system of 37,000 AI agents analyzed 55,984 clinical trials and proposed CD276 (B7-H3) as a lung-cancer target using an antibody-drug conjugate strategy. No molecule was synthesized or tested in humans; the recommendation was indirectly validated by Merck and Daiichi Sankyo's CD276 program, which received FDA breakthrough designation.

• 37,000 agents processed 55,984 clinical trials
• Proposed an antibody-drug conjugate strategy against CD276 (B7-H3)
• Merck and Daiichi Sankyo's CD276 program got FDA breakthrough status
• No molecule was synthesized or tested in humans